Status:
COMPLETED
Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
Swiss Federal Institute of Technology
Conditions:
Healthy
Schizotypal Personality
Eligibility:
MALE
20-60 years
Phase:
EARLY_PHASE1
Brief Summary
The dopamine hypothesis of schizophrenia implies that alterations in the dopamine system cause functional abnormalities in the brain that may converge to aberrant salience attribution and eventually l...
Eligibility Criteria
Inclusion
- Healthy,
- Between 20 and 40 years of age,
- With exceptional experiences or skeptics,
- Caucasian origin,
- Normal visual and acoustic accuracy.
Exclusion
- Persons with a personal or first-degree family history of neurological and psychiatric disease, including impaired cognitive abilities,
- Pregnant or breastfeeding women,
- Chronic or acute pain,
- Acute or chronic somatic disease,
- Women (i.e. only men included),
- Men over 40 years of age or below 20,
- left- or mixed-handedness,
- General MRI exclusion criteria,
- General Dopamine-Challenge exclusion criteria,
- Hormonal or herbal therapy,
- Smoker.
Key Trial Info
Start Date :
May 15 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 13 2015
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT03333369
Start Date
May 15 2014
End Date
August 13 2015
Last Update
November 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Collegium Helveticum, ETH & Universität Zürich
Zurich, Switzerland, 8006 Zürich